DNER and breast carcinoma: A large number of studies have indicated that BET inhibitors may be beneficial in the treatment of hematological malignancies and solid tumours including breast cancer, possibly by inhibiting certain key proto-oncogenes such as MYC (Jiang et al., 2020).